Trial Profile
Pivotal phase II/III trial of a house dust mite allergy immunotherapy tablet in patients with house dust mite-induced allergic rhinitis
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 04 Jan 2022
Price :
$35
*
At a glance
- Drugs House dust mite allergy immunotherapy-ALK Abello (Primary)
- Indications Allergic rhinitis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Torii Pharmaceutical
- 08 Nov 2021 Results of pooled post hoc analysis comparing efficacy and safety of the HDM SLIT-tablet between adults and adolescents by using data from two studies (NCT01700192 an JapicCTI21848) presented at the 2021 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
- 01 Mar 2021 Results assessing efficacy and safety data from 2 clinical trials (NCT01700192 and JapicCTI121848), presented at the 2021 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 06 Mar 2017 A Subgroup Analysis of Results from a DBPC Phase III Trial presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology